Can persistently low vitamin D and magnesium despite supplementation reflect absorption or utilization issues?

When systemic levels of vitamin D and magnesium remain persistently low despite oral supplementation, the underlying cause is frequently physiological or pharmacological rather than a simple lack of compliance.

Bioavailability and formulation differences

• Chemical formulation: The specific molecular form of a supplement heavily dictates its fractional absorption. For example, inorganic magnesium oxide has a highly limited bioavailability of approximately 4%, whereas organic chelates such as magnesium glycinate and magnesium citrate leverage active transport and peptide pathways to achieve significantly higher fractional absorption rates between 40% and 80%.
• Gastrointestinal barriers: Underlying clinical conditions like celiac disease or inflammatory bowel disease (IBD) disrupt the mucosal surface, severely impairing the uptake of both divalent minerals and fat-soluble vitamins, rendering standard oral doses clinically ineffective.

Mechanistic synergy and utilization

• Enzymatic cofactors: Magnesium acts as a critical, rate-limiting cofactor for the enzymes responsible for vitamin D metabolism, specifically 25-hydroxylase in the liver and 1α-hydroxylase in the kidneys.
• Transport and activation: Low systemic magnesium impairs the function of vitamin D-binding protein (VDBP) and prevents the enzymatic conversion of vitamin D into its biologically active form. This metabolic bottleneck creates a state of functional vitamin D resistance, meaning vitamin D levels cannot be successfully repleted without concurrently correcting the underlying magnesium deficit.

Bottom line

• Persistent deficiencies of vitamin D and magnesium despite oral supplementation are frequently driven by poor formulation bioavailability (such as utilizing low-yield magnesium oxide) or metabolic interdependencies, where severe magnesium deficiency biochemically blocks the transport and activation of vitamin D.